A study on the bioequivalence of lithium and valproate salivary and blood levels in the treatment of bipolar disorder
- 1 August 2017
- journal article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 27 (8) , 744-750
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Economía y Competitividad
- Instituto de Salud Carlos III
- European Commission (2014_SGR_398)
- European Regional Development Fund
This publication has 45 references indexed in Scilit:
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Bipolar Disorders, 2012
- Survey of the prevalence of immunization non-compliance due to needle fears in children and adultsVaccine, 2012
- Development and validation of a bioanalytical LC-UV method with solid-phase extraction for determination of valproic acid in salivaActa Pharmaceutica, 2012
- Polarity index of pharmacological agents used for maintenance treatment of bipolar disorderEuropean Neuropsychopharmacology, 2012
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Assessment of Medication Adherence in a Cohort of Patients with Bipolar DisorderPharmacopsychiatry, 2010
- Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinicComprehensive Psychiatry, 2009
- Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic StrategiesEpilepsia, 2008
- Therapeutic Drug Concentration Monitoring Using Saliva SamplesClinical Pharmacokinetics, 1999
- Therapeutic Drug Monitoring in SalivaClinical Pharmacokinetics, 1978